A Hungarian biotechnology R&D company is developing a novel platform for isolation of extracellular vesicles from biofluids. The device enables high-quality, scalable, and cost-efficient isolation from any biofluid. The company seeks partners to develop the platform to a market-ready device in the H2020 EIC-FTI call. Partners needed: (1) manufacturing company with strong market position and distribution network, (2) university research group with experience in extracellular vesicles research.
Exosomes are small, cell-derived lipid vesicles that play key roles in intercellular communication. Despite their outstanding potential in diagnostic and therapeutic use, the transition of exosome-based applications from laboratory research to clinical practice is hindered by the lack of a gold standard, optimal technology for the isolation of exosomes from bodily fluids. The novel platform provides the solution to the above problem. It is a highly effective isolation platform for exosomes, with high throughput, good reproducibility, decreasing the required effort and time for isolation. The innovative platform is essentially scalable, has low initial costs, and requires minimal experience from the user. Therefore, its widespread use will decrease the barriers for exosome-based applications. The aim is to provide a special equipment, customised consumables, and methodology to the specific needs in exosome isolation from different biofluids, such as blood or urine. The coordinator of the planned project is a Hungarian biotechnology R&D company developing novel in-house R&D projects and providing innovative preclinical and clinical R&D services since 2003. The company is a worldwide R&D service provider with opinion leader scientific management. As technological development of the device has reached the prototype stage, the coordinator company is now preparing for further development in a Fast Track to Innovation project. The planned project will build upon the SME Instrument Phase 1 project recently carried out by the coordinator company. The deadline for the targeted call (EIC-FTI) is 27 October 2020. The project will be carried out by a small consortia of 3 to 5 partners. Partners sought: - manufacturing company with strong market position and distribution network. Tasks: manufacturing of the novel extracellular vesicles isolation platform - academic research group with outstanding scientific excellence in extracellular vesicles research. Tasks: isolation of targeted, specific sub-population of extracellular vesicles Deadline for EOIs: 30 September 2020.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
Partner 1 - Type of partner sought: Industry - Specific area of activity of the partner: Commercial production and/or distribution of laboratory equipment and/or medical devices, In Vitro Diagnostics - Task to be performed: During the project the partner’s tasks will include contribution to the requirements specification; manufacturing of the novel extracellular vesicles isolation platform; and contribution to dissemination and exploitation activities aiding future commercialization. After the project, the partner would be involved in the commercialization of the project results, providing the novel extracellular vesicles isolation platform to be used by research laboratories. Partner 2 - Type of partner sought: Academic Research Group - Specific area of activity of the partner: Isolation of targeted, specific sub-population of extracellular vesicles as well as validation of performance of the isolation platform. - Task to be performed: testing the novel extracellular vesicles isolation platform in their everyday laboratory practice by isolation of targeted, specific sub-population of extracellular vesicles.
Stage of Development:
Prototype available for demonstration